IOBTQ · IO Biotech, Inc.
$0.00
+0.00 (+0.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern. As a result, the financial statements accompanying this Quarterly Report on Form 10-Q include a statement that there is substantial doubt about our ability to continue as a going concern for one year after the date the financial statements were issued, and these financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.”View the 10-Q filed Nov 14, 2025
Market Cap
$7,194
Shares
71.95M
Volume · Oct 2
600
Avg daily vol (3M)
110K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–1.17
Avg vol 30d25K
Short int471K · 0.7% float · 7.4d
Short vol16%
Last earningsNov 14, 2025
DataNov 2021–Oct 2026
Filing10-Q · Nov 14
Up next
filed Nov 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-100.0%
Trailing year
Short interest
0.7%
Latest settlement · 7.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−100%
below
Price vs 50-day avg
−89%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+100%
trailing
6-month return
−100%
trailing
YTD return
−100%
this year
Relative strength
−112%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-45% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.65% of float · ▬ 0.0% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
12 holders — near 3-yr low, contrarian setup
Squeeze score
32
low risk · 0–100
Fundamentals
EPS growth
+27%
Y/Y
Free cash flow
$-82.4M
Balance sheet
$60.0M
net cash
Quant / Vol
risk profile
Volatility
1953%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
150.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−100%
Bearish
Price vs 50-day avg
−89%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-45% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.65% of float · ▬ 0.0% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
12 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $1
vs 200-day avg -100%
vs 50-day avg -89%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IOBTQ
this stock
IO Biotech, Inc.
|
$7,194 | -100.0% | — | — | 0.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
12
- % held
- 4.7%
- Net QoQ
- -4.5M sh
- Top holder
- Ikarian Capital, LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IOBTQ | +0.0% | +100.0% | -99.9% | +100.0% | -100.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.2% | +100.5% | -112.1% | +99.1% | -112.8% |